Last reviewed · How we verify
Synergy for Pseudomonas Aeruginosa Joint Infection
Approved treatments
- Ramycin
Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins. - Garamycin · Merck & Co.
- Gentamicin · Merck & Co.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Synergy for Pseudomonas Aeruginosa Joint Infection patent landscape — cliff calendar, originator estates, attackable patents
- Synergy for Pseudomonas Aeruginosa Joint Infection treatment landscape brief
- Synergy for Pseudomonas Aeruginosa Joint Infection treatment updates RSS
Frequently asked questions about Synergy for Pseudomonas Aeruginosa Joint Infection
What drugs treat Synergy for Pseudomonas Aeruginosa Joint Infection?
Tracked treatments include Ramycin, Garamycin, Gentamicin.
What is the treatment for Synergy for Pseudomonas Aeruginosa Joint Infection?
Standard treatment for Synergy for Pseudomonas Aeruginosa Joint Infection includes Ramycin, Garamycin, Gentamicin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Synergy for Pseudomonas Aeruginosa Joint Infection patent cliff · Synergy for Pseudomonas Aeruginosa Joint Infection CI report
- Treatment: Ramycin
- Treatment: Garamycin · Merck & Co.
- Treatment: Gentamicin · Merck & Co.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing